title: Second trimester medical abortion with mifepristone followed by unlimited dosing of buccal misoprostol in Armenia.
abstract: OBJECTIVE
  The aim of the study was to assess the efficacy and acceptability of a regimen using mifepristone and buccal misoprostol with unlimited dosing for second trimester abortion in Armenia.
  
  
  METHODS
  Women seeking to terminate 13-22 week pregnancies were enrolled in the study. Participants swallowed 200 mg mifepristone in the clinic and were instructed to return to the hospital for induction 24-48 h later. During induction, women were given 400 μg buccal misoprostol every 3 h until the fetus and placenta were expelled. The abortion was considered a success if complete uterine evacuation was achieved without oxytocin or surgery.
  
  
  RESULTS
  A total of 120 women with a median gestational age of 18 weeks participated in the study. All women began misoprostol induction around 24 h after taking mifepristone. Complete uterine evacuation was achieved in 119 (99.2%) women. The median induction-to-abortion interval was 10.3 h (range 4-17.4) with a mean of 9.5 ± 2.5 h. A median of four misoprostol doses (range 2-6) with a mean of 4 ± 1 misoprostol doses were administered. The induction-to-abortion interval, number of misoprostol doses, pain score and analgesia use increased as gestational age advanced. Acceptability of the method was high among both patients and providers.
  
  
  CONCLUSIONS
  The medical abortion regimen of 200 mg mifepristone followed 24 h later by induction with 400 μg buccal misoprostol administered every 3 h, with no limit on the number of doses used for the termination of pregnancies of 13-22 weeks' gestation is an effective and acceptable option for women.
authors.affiliation: a Gynuity Health Projects , New York , NY , USA.
authors.forename: Karmen S
authors.initials: KS
authors.lastname: Louie
authors.affiliation: a Gynuity Health Projects , New York , NY , USA.
authors.forename: Erica
authors.initials: E
authors.lastname: Chong
authors.affiliation: b Gynuity Health Projects , Tbilisi , Georgia.
authors.forename: Tamar
authors.initials: T
authors.lastname: Tsereteli
authors.affiliation: c Department of Obstetrics and Gynaecology No2 , Yerevan State Medical University , Yerevan , Armenia.
authors.forename: Gayane
authors.initials: G
authors.lastname: Avagyan
authors.affiliation: d Republican Institute of Reproductive Health, Perinatology, Obstetrics and Gynaecology , Yerevan , Armenia.
authors.forename: Ruzanna
authors.initials: R
authors.lastname: Abrahamyan
authors.affiliation: a Gynuity Health Projects , New York , NY , USA.
authors.forename: Beverly
authors.initials: B
authors.lastname: Winikoff
mesh_terms: D000019:Abortifacient Agents / Q000008:administration & dosage*; D000028:Abortion, Induced / Q000379:methods*; D000278:Administration, Buccal; D000328:Adult; D001136:Armenia; D004334:Drug Administration Schedule; D005260:Female; D005865:Gestational Age; D006801:Humans; D015735:Mifepristone / Q000008:administration & dosage*; D016595:Misoprostol / Q000008:administration & dosage*; D011247:Pregnancy; D011262:Pregnancy Trimester, Second; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000019:Abortifacient Agents; D016595:Misoprostol; D015735:Mifepristone
keywords: Armenia; medical abortion; mifepristone; misoprostol; second trimester